Results 1 to 10 of about 471 (127)

Resistance of Gram-Negative Bacteria to Cefepime-Enmetazobactam: A Systematic Review [PDF]

open access: yesPathogens
Cefepime-enmetazobactam is a novel β-lactam/β-lactamase inhibitor combination showing good activity against multidrug-resistant (MDR) Gram-negative bacteria producing a variety of β-lactamases.
Dimitrios S Kontogiannis   +1 more
exaly   +8 more sources

Real-world outcomes of cefepime/enmetazobactam for Enterobacterales infections: a retrospective descriptive study [PDF]

open access: yesMicrobiology Spectrum
Cefepime/enmetazobactam (FEP/META) is a novel β-lactam/β-lactamase inhibitor combination with activity against Enterobacterales, including extended-spectrum β-lactamase-producing isolates, but real-world clinical data outside randomized trials remain ...
Cecilia Bonazzetti   +29 more
doaj   +6 more sources

Third-Generation Cephalosporin Resistance in Clinical Isolates of Enterobacterales Collected Between 2016–2018 From USA and Europe: Genotypic Analysis of β-Lactamases and Comparative in Vitro Activity of Cefepime/Enmetazobactam

open access: yesJournal of Global Antimicrobial Resistance, 2021
: Objectives: This study aimed to investigate third-generation cephalosporin (3GC) resistance determinants [extended-spectrum β-lactamases (ESBLs), AmpC β-lactamases and OXA-type β-lactamases] in contemporary clinical Enterobacterales isolates and to ...
Stephen Hawser   +2 more
exaly   +4 more sources

Ventilator-Associated Pneumonia Due to ESBL-Producing Escherichia coli Successfully Treated with Cefepime/Enmetazobactam: A European Case Report [PDF]

open access: yesInfectious Diseases and Therapy
Extended-spectrum β-lactamase (ESBL)-producing Enterobacterales represent a growing cause of ventilator- associated pneumonia (VAP) in critically ill patients.
Bruno Viaggi   +6 more
doaj   +3 more sources

Antibacterial activity of enmetazobactam against Acinetobacter spp.: a molecular dissection of mechanism of action and resistance determinants [PDF]

open access: yesAntimicrobial Agents and Chemotherapy
The persistence of multidrug-resistant Acinetobacter baumannii remains a clinical challenge. Cefepime/enmetazobactam is a novel combination with demonstrated activity against extended-spectrum β-lactamase-producing Enterobacterales, but its activity ...
Gabriela-Alejandra Báez-Barroso   +15 more
doaj   +8 more sources

ESBL-Producing Klebsiella pneumoniae Bacteraemia with Renal Micro-Abscesses Treated with Cefepime–Enmetazobactam in a Neutropenic Allogeneic Transplant Recipient [PDF]

open access: yesPathogens
Extended-spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae causes difficult-to-treat bloodstream infections in patients with haematological malignancies, particularly after allogeneic haematopoietic stem cell transplantation (allo-HSCT ...
Carlo Tascini   +7 more
doaj   +3 more sources

Cefepime and New Cefepime/Beta-Lactamase Inhibitor Combination for the Treatment of Gram-Negative Bacteria: Chemical Structure and Mechanism of Action, Microbiological Target, Clinical Use and PK/PD Characteristics [PDF]

open access: yesPharmaceuticals
The global spread of multidrug-resistant (MDR) Gram-negative bacteria, particularly extended-spectrum β-lactamase (ESBL)- and carbapenemase-producing Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii, presents a significant public ...
Davide Carcione   +16 more
doaj   +3 more sources

Cefepime 2.0: Upgrading β-Lactamase Inhibitor Use [PDF]

open access: yesMicroorganisms
Antimicrobial resistance (AMR) in Gram-negative pathogens represents a critical global health challenge. Combining cefepime with novel β-lactamase inhibitors (enmetazobactam, taniborbactam, zidebactam, and nacubactam) revitalizes the role of this fourth ...
Francesco Giuseppe De Rosa   +6 more
doaj   +2 more sources

Cefepime Combined with Late-Generation β-Lactamase Inhibitors: Mechanisms of Action, In Vitro Activity, PK/PD Characteristics, Clinical Evidence and Resistance Mechanisms [PDF]

open access: yesAntibiotics
Cefepime combined with late-generation β-lactamase inhibitors—enmetazobactam, zidebactam, and taniborbactam—represents a promising strategy to treat multidrug-resistant Gram-negative infections.
Sara Comini   +3 more
doaj   +2 more sources

Clinical, Microbiological and Genomic Characterization of OXA-48-Producing Klebsiella pneumoniae ST395 Circulating in a Secondary-Care Hospital in North-Eastern Italy, 2024–2025 [PDF]

open access: yesAntibiotics
Background/Objectives: This study aimed to characterize the epidemiology, resistance, virulence determinants, and genomic relatedness of OXA-48-producing Klebsiella pneumoniae in a secondary-care hospital in north-eastern Italy, and to assess the in ...
Simone Giuliano   +13 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy